In-PharmaTechnologist presents its weekly round-up of the latest new appointments in the pharma biz, including news from Pfizer, EMD Millipore and Jubilant.
Pfizer has made Olivier Brandicourt president and general manager of emerging markets and established products.
Previously, he was president and general manager of the firm’s primary care business unit.
Ian Read, CEO, said: “Olivier is both a physician and proven business leader who understands the many challenges of today’s changing industry and healthcare landscape.”
Brandicourt takes over from David Simmons, who is leaving Pfizer to become CEO of Pharmaceutical Product Development (PPD).
Merck KGaA’s life sciences subsidiary EMD Millipore has hired John Sweeney as head of the bioscience business unit.
Sweeney first joined the firm in 2003, working his way up from the strategy and corporate development department, to becoming VP of strategy and marketing services most recently.
Robert Yates, president, said: “His demonstrated success and expertise will offer new insights and perspectives for continued growth and opportunity within the bioscience business.”
Israel Makov has become chairman of the board for Indian speciality therapy maker Sun Pharmaceutical.
Formerly the President and CEO of Teva Pharmaceuticals, Sun hopes Makov’s appointment will help drive its global expansions.
Managing director Dilip Shanghvi said: “As Sun Pharma continues to rapidly expand its presence worldwide, I am sure that we will benefit immensely from his experience.”
InVivo Therapeutics Holdings has drafted inRobert Housler as VP of business development.
In his new role, Housler will help drive the company’s new growth plans by establishing strategic relationships and partnerships.
Previously, he was director of strategic sales at Stryker Spine.
CEO of Merrion Pharmaceuticals, Jonathan O'Connell, is set to leave the firm in June.
O’Connell leaves after just over one year in the role, during which time he set the company on a new strategic course, says the firm.
Current chair Michael Donnelly will take over in his stead.
Commenting on his departure, O'Connell said: “It became clear that my job here was nearing completion as the restructuring of the business is on a clear execution path with a sound financial footing. Therefore I have informed the board of my decision to step down as CEO and not to seek re-election to the board at the forthcoming AGM.”